Estimation of psycholeptic and psychoanaleptic medicine use in an adult general population sample using the Anatomical Therapeutic Chemical classification

Int J Methods Psychiatr Res. 2008;17(4):220-31. doi: 10.1002/mpr.263.

Abstract

Little is known about psycholeptic and psychoanaleptic medicine (PM) use in the general population. This study presents prevalence data about PM use. The sample included 4310 individuals aged 20-79 from a general population health examination in a northern German area (participation proportion: 68.8%; Study of Health in Pomerania, SHIP). Medicines taken during the past seven days were assessed from the medicine packages or self-reports and classified according to the Anatomical Therapeutic Chemical (ATC) classification developed by the World Health Organization. In total, 6.3% of the sample reported PM intake, 8.7% of the women and 4.7% of the men. During the past 12 months prior to the health examination, 49.2% of the individuals with PM use consulted a general practitioner but not a neurologist or a psychiatrist. Among the study participants with PM use, 88.8% had one or more mental disorders during lifetime according to a screening questionnaire. It is concluded that considerable proportions of individuals with current PM use exist although lower than may be expected on the basis of the number of individuals with mental disorder in the general population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Central Nervous System Stimulants / therapeutic use*
  • Drug Utilization / statistics & numerical data
  • Family Practice / statistics & numerical data
  • Female
  • Germany
  • Humans
  • Male
  • Mass Screening / statistics & numerical data*
  • Mental Disorders / drug therapy
  • Mental Disorders / epidemiology
  • Middle Aged
  • Neurology / statistics & numerical data
  • Psychiatry / statistics & numerical data
  • Psychotropic Drugs / therapeutic use*
  • Referral and Consultation / statistics & numerical data
  • Utilization Review
  • Young Adult

Substances

  • Central Nervous System Stimulants
  • Psychotropic Drugs